The longevity science movement has produced a parallel commercial sector: private longevity clinics that offer systematic biological age testing and personalized anti-aging protocols to paying clients. MIT Technology Review counted more than 82 such clinics globally in 2024, with concentrations in California, Switzerland, Dubai, Singapore, and Japan. The services range from well-grounded preventive medicine to poorly evidenced therapies wrapped in scientific language.
## What Longevity Clinics Offer
Most clinics anchor their services around a diagnostic phase followed by a personalized intervention plan.
**Diagnostics** typically include: whole-genome sequencing; epigenetic age clocks (GlycanAge, TruAge, Horvath’s methylation clock); proteomics panels (Olink); metabolomics; microbiome analysis; whole-body MRI; liquid biopsy (ctDNA cancer screening); and continuous glucose monitoring.
**Lifestyle interventions** include: personalized nutrition (often incorporating fasting or time-restricted eating); exercise prescriptions optimized for VO₂max and strength; sleep protocols; and stress management. These are generally well-supported by evidence.
**Supplement protocols** vary widely: NAD⁺ precursors (NMN, NR), resveratrol, quercetin, spermidine, and low-dose rapamycin appear on many lists. Evidence quality ranges from moderate (NAD⁺ precursors, rapamycin) to thin (most others).
**Frontier therapies** with limited evidence: plasma exchange or young plasma infusions; stem cell injections; exosome therapy; hyperbaric oxygen; ozone therapy. These are typically offered at high cost with minimal clinical validation.
## Bryan Johnson’s Blueprint
Tech entrepreneur Bryan Johnson has become the public face of systematic personal longevity optimization. His “Blueprint” protocol is fully public and includes: a precise 1,977-calorie daily diet, 111 daily supplements, a structured exercise program, aggressive sleep optimization, and thorough quarterly biomarker testing. Reported cost: approximately $2 million per year.
Johnson claims multiple biomarkers show biological ages significantly younger than his chronological age (heart age 37, actual age 46). The scientific community has noted that self-reported results lack control groups, outcome selection may favor positive results, and individual variation makes single-case data hard to interpret. See [Blueprint](https://blueprint.bryanjohnson.co/) for the full protocol.
## The Evidence Gap
The diagnostic component of longevity medicine — systematic biomarker testing, early disease detection, personalized lifestyle guidance — is well-supported. The intervention protocols based on caloric restriction, exercise, and sleep optimization have solid evidence.
Many of the higher-priced frontier therapies do not. Young plasma infusion lacks strong human evidence; the FDA has warned against its use. Stem cell injections outside clinical trials carry real risks. Hyperbaric oxygen shows inconsistent results across trials.
The core tension in the longevity clinic industry is between legitimate preventive medicine, which is genuinely valuable, and poorly evidenced therapies presented in scientific-sounding language. Consumers benefit from distinguishing the two. For the underlying science, see [Hallmarks of Aging](https://sunqi.org/aging-biology-hallmarks-en/) and [MIT Technology Review](https://www.technologyreview.com/2024/06/14/1093489/longevity-clinics/).
—
